skip to Main Content

April 4, 2021
TAG Comments on NIST’s Proposed Rulemaking Changes
Letter / Comment
TAG submitted comments in response to the National Institute of Standards and Technology’s (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically…

April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…

February 25, 2021
Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
Letter / Comment
TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and by lowering cost of its tests for SARS-CoV-2, TB, HIV, HCV, and other diseases…

February 3, 2021
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
Webinar / Presentation
On February 3, 2021, TAG, Médecins du Monde, hepCoalition, and the UNITE network presented a virtual policy dialogue among policymakers, global civil society organizations, and community leaders who share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

February 1, 2021
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
Statement / Press
On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

February 1, 2021
Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination
Publication
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

December 11, 2020
2020 TAG Update
Publication
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

November 11, 2020
TAGline November 2020
TAGline
‘The Struggle of a Lifetime’ (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before…

November 9, 2020
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

November 9, 2020
TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris
Statement / Press
Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.

Back To Top